1. Home
  2. ANL vs CTY Comparison

ANL vs CTY Comparison

Compare ANL & CTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

CTY

City Therapeutics Inc. Common Stock

N/A

Current Price

$17.44

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANL
CTY
Founded
2004
2023
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
1.0B
IPO Year
2022
2026

Fundamental Metrics

Financial Performance
Metric
ANL
CTY
Price
$10.80
$17.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
$29.50
★ $37.33
AVG Volume (30 Days)
★ 268.1K
238.1K
Earning Date
08-14-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$243.83
$62.96
Revenue Next Year
N/A
$7.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$15.81
52 Week High
$17.25
$22.65

Technical Indicators

Market Signals
Indicator
ANL
CTY
Relative Strength Index (RSI) 46.74 39.86
Support Level $8.95 $16.01
Resistance Level $11.90 $21.98
Average True Range (ATR) 0.99 2.22
MACD 0.25 -0.20
Stochastic Oscillator 72.55 23.83

Price Performance

Historical Comparison
ANL
CTY

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About CTY City Therapeutics Inc. Common Stock

City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.

Share on Social Networks: